
Biogen Inc.
BIIBHealthcare|Drug Manufacturers - General|US
$248.35
+4.42 (+1.81%)
DCF Value
$517.66
Graham Number
$82.35
Cash / Share
$8.82
Clinical Trials (515)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07223723 A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | P4 | Active | 12 | Open-label | Tofersen |
| NCT04468659 AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid | Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease | P3 | Active | 1,400 | RCT, Double-blind | Lecanemab, Placebo |
| NCT03887455 A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | Early Alzheimer's Disease | P3 | Active | 1,906 | RCT, Double-blind | Lecanemab IV, Placebo, Lecanemab SC |
| NCT06935357 A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) | Immunoglobulin A Nephropathy (IgAN) | P3 | Recruiting | 454 | RCT, Double-blind | Felzartamab, Placebo |
| NCT04961567 A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus | Lupus Erythematosus, Systemic | P3 | Active | 562 | RCT, Double-blind | Litifilimab, Placebo |
| NCT05067790 A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND) | Spinal Muscular Atrophy | P3 | Active | 45 | Open-label | Nusinersen |
| NCT07444476 A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam | Spinal Muscular Atrophy | P3 | Recruiting | 90 | Open-label | Salanersen |
| NCT07444450 A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec | Muscular Atrophy, Spinal | P3 | Recruiting | 42 | RCT, Double-blind | Salanersen |
| NCT06953583 A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia | Friedreich Ataxia | P3 | Active | 255 | RCT, Double-blind | Omaveloxolone, Placebo |
| NCT05531565 A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus | P2P3 | Active | 450 | RCT, Double-blind | Litifilimab, Placebo |
| NCT07221669 A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA) | Muscular Atrophy, Spinal | P3 | Recruiting | 30 | Open-label | Salanersen |
| NCT06602193 Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) | Parkinson Disease | P2 | Active | 50 | RCT, Double-blind | BIIB122 225 mg |
| NCT07294144 Tofersen in Non-SOD1 ALS | ALS (Amyotrophic Lateral Sclerosis) | P2 | Recruiting | 30 | Open-label | Tofersen |
| NCT05418010 Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS) | Multiple Sclerosis, Clinically Isolated Syndrome of Demyelination | P2 | Recruiting | 40 | RCT, Double-blind | Tyruko Injectable Product, Placebo |
| NCT07722546 A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old | Graves' Disease | P2 | Recruiting | 60 | RCT, Double-blind | Felzartamab, Placebo |
| NCT06555419 A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK) | Muscular Atrophy, Spinal | P1 | Recruiting | 78 | Open-label | Nusinersen |
| NCT07133828 A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years Old | Healthy Volunteer | P1 | Recruiting | 78 | RCT, Double-blind | BIIB142, BIIB142-Matching Placebo |
| NCT06054893 A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old | Friedreich Ataxia | P1 | Active | 33 | Open-label | Omaveloxolone |
| NCT07662148 A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it is Processed in the Body of Healthy Adult Participants Ages 18 to 55 Years Old as Compared to a Placebo | Healthy Volunteer | P1 | Recruiting | 48 | RCT, Double-blind | BIIB144, Placebo |
| NCT05575011 A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec | Healthy Volunteer, Muscular Atrophy, Spinal | P1 | Active | 62 | RCT, Double-blind | BIIB115, BIIB115-Matching Placebo |
| NCT03047369 The Myelin Disorders Biorepository Project | Leukodystrophy, White Matter Disease | Recruiting | 12,000 | — | — | |
| NCT05866419 Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy | Spinal Muscular Atrophy, Spine Deformity | N/A | Recruiting | 90 | Open-label | — |
| NCT01848028 PsoBest - The German Psoriasis Registry | Psoriasis, Psoriatic-arthritis | Recruiting | 3,500 | — | — | |
| NCT05658497 Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate) | Multiple Sclerosis | Recruiting | 908 | — | Diroximel Fumarate, Avonex, Tysabri, Dimethyl Fumarate | |
| NCT05618379 Adult Spinal Muscular Atrophy (SMA) China Registry | Muscular Atrophy, Spinal | Active | 200 | — | — | |
| NCT05767736 A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS) | Multiple Sclerosis | Active | 10,500 | — | Diroximel Fumarate, Dimethyl Fumarate, Disease-Modifying Therapies (DMTs) | |
| NCT07433010 German Dementia Registry | Dementia Disorder | Recruiting | 5,000 | — | — | |
| NCT07259980 A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Recruiting | 125 | — | Tofersen | |
| NCT06623890 A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors | Friedreich Ataxia | Recruiting | 300 | — | Omaveloxolone | |
| NCT06978985 Adult SMA Research and Clinical Hub | Spinal Muscular Atrophy (SMA) | Recruiting | 600 | — | Risdiplam, Nusinersen Injectable Product | |
| NCT06955897 Characterizing Perceived Physical Fatigability in Nusinersen-treated SMA | Spinal Muscular Atrophy | Recruiting | 45 | — | — | |
| NCT05042921 Pediatric Spinal Muscular Atrophy (SMA) China Registry | Muscular Atrophy, Spinal | Active | 600 | — | — | |
| NCT05789758 A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies | Muscular Atrophy, Spinal | Recruiting | 20 | — | — | |
| NCT05925049 A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS) | Multiple Sclerosis | Active | 400 | — | Natalizumab | |
| NCT06053749 An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden | Multiple Sclerosis (MS) | Active | 4 | — | Avonex (IFNβ-1-a, Biogen Netherlands B.V), Rebif (IFNβ-1-a, Merck Europe B.V.), Extavia (IFNβ-1-b, Novartis Europharm Limited), Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG), Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V), MS disease modifying drugs (MSDMDs) | |
| NCT07400198 Gait and Bone Health in SMA | Spinal Muscular Atrophy Type 3, Ambulatory Spinal Muscular Atrophy | Recruiting | 22 | — | — | |
| NCT04317794 A Study of the Safety of Nusinersen (Spinraza®) and Its Effects on Motor Function in Koreans Living With SMA Treated During Their Usual Medical Care | Muscular Atrophy, Spinal | Active | 74 | — | Nusinersen Sodium Injection | |
| NCT06628687 A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies | Friedreich Ataxia | Recruiting | 10 | — | Omaveloxolone | |
| NCT07398469 A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone | Postpartum Depression | Recruiting | 300 | — | Zuranolone | |
| NCT05017142 Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD) | Optic Neuritis, Transverse Myelitis | Recruiting | 500 | — | — | |
| NCT04292574 UK SMA Patient Registry | Spinal Muscular Atrophy, SMA | Recruiting | 800 | — | — | |
| NCT00168753 Community Based Trial for AMEVIVE® | Moderate to Severe Chronic Plaque Psoriasis | P4 | Completed | 114 | Open-label | Alefacept |
| NCT04048577 A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab | Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | P4 | Unknown | 10 | Open-label | Dosing Interruption of Natalizumab |
| NCT03424733 Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects | Multiple Sclerosis | P4 | Unknown | 50 | Open-label | Plegridy, Prednisone, Tylenol Pill |
| NCT00498368 Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy | IgA Nephropathy | P4 | Completed | 34 | RCT, Open-label | Intravenous Rituximab, ACE/ARB |
| NCT00574041 How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose | Relapsing Remitting Multiple Sclerosis | P4 | Terminated | 19 | RCT, Single-blind | Interferon beta-1a |
| NCT00492466 Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies | Relapsing-Remitting Multiple Sclerosis | P4 | Completed | 14 | Open-label | Interferon-beta-1a, methylprednisolone |
| NCT02461069 Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | P4 | Completed | 67 | Open-label | Dimethyl fumarate |
| NCT00913666 Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers | Multiple Sclerosis | P4 | Completed | 121 | Single-blind | Interferon beta-1a (Avonex) |
| NCT00536120 The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis | Multiple Sclerosis | P4 | Completed | 60 | RCT, Open-label | BG00002 (natalizumab), keyhole limpet hemocyanin (KLH), tetanus diphtheria toxoid vaccine (Td) |
| NCT00168766 Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS | Relapsing-remitting Multiple Sclerosis | P4 | Completed | 345 | RCT, Double-blind | Interferon-beta-1a (Avonex) plus methylprednisolone |
| NCT00493116 Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta | Relapsing-Remitting Multiple Sclerosis | P4 | Completed | 20 | Open-label | Interferon-beta-1a, methylprednisolone |
| NCT00801125 Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy | Crohn's Disease | P4 | Withdrawn | — | Open-label | natalizumab |
| NCT00744679 A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State | Multiple Sclerosis | P4 | Completed | 20 | Open-label | Natalizumab |
| NCT02471560 Tecfidera and the Gut Microbiota | Multiple Sclerosis, Relapsing-Remitting | P4 | Completed | 36 | Open-label | dimethyl fumarate, injectable MS DMT |
| NCT00090038 Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | P4 | Completed | 168 | Open-label | rituximab |
| NCT00771043 A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a | Relapsing-remitting Multiple Sclerosis | P4 | Withdrawn | — | RCT, Open-label | TYSABRI and AVONEX |
| NCT01873417 Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States | Relapsing Forms of Multiple Sclerosis | P4 | Completed | 237 | Open-label | BG00012 (DMF) |
| NCT02410278 Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera | Multiple Sclerosis | P4 | Completed | 102 | RCT, Double-blind | dimethyl fumarate, montelukast, Placebo |
| NCT05177718 Natalizumab and Chronic Inflammation | Multiple Sclerosis | P4 | Terminated | 1 | Open-label | Natalizumab 300 MG in 15 ML Injection |
| NCT02739542 Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS) | Multiple Sclerosis (MS) | P4 | Completed | 87 | RCT, Double-blind | Tecfidera, Placebo |
| NCT00168727 Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma | Lymphoma, Non-Hodgkin, Lymphoma, Low-Grade | P4 | Completed | 12 | Open-label | ibritumomab tiuxetan (Zevalin®) |
| NCT01767493 Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients | Multiple Sclerosis | P4 | Completed | 19 | Open-label | [18F]Florbetapir PET imaging |
| NCT05658484 A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China | Multiple Sclerosis | P4 | Completed | 60 | Open-label | Dimethyl fumarate |
| NCT02143167 Resistance Training and Amino Pyridine in Multiple Sclerosis | Multiple Sclerosis | P4 | Completed | 40 | RCT, Double-blind | SR-fampridine, Placebo |
| NCT02587065 Plegridy Satisfaction Study in Participants | Relapsing-Remitting Multiple Sclerosis (RRMS) | P4 | Completed | 193 | Open-label | peginterferon beta-1a |
| NCT03177083 Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy | Relapsing Remitting Multiple Sclerosis | P4 | Completed | 80 | RCT, Open-label | peginterferon beta-1a, interferon beta-1a, interferon beta-1b |
| NCT03092544 Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients | Multiple Sclerosis | P4 | Unknown | 57 | Open-label | dimethyl fumarate |
| NCT01480076 Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis | Multiple Sclerosis | P4 | Completed | 901 | Open-label | Fampridine |
| NCT01211665 Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS) | Immune Reconstitution Inflammatory Syndrome, Leukoencephalopathy, Progressive Multifocal | P4 | Terminated | 3 | Open-label | Methylprednisolone, Prednisolone |
| NCT00280956 Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease | Crohn's Disease | P4 | Completed | 2,000 | Open-label | natalizumab |
| NCT02142205 Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS) | Relapsing-Remitting Multiple Sclerosis | P4 | Completed | 100 | Open-label | BG00002 |
| NCT02090348 Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate | Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis | P4 | Withdrawn | — | Open-label | dimethyl fumarate |
| NCT02343159 Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients. | Multiple Sclerosis | P4 | Terminated | 84 | RCT, Open-label | dimethyl fumarate |
| NCT02568111 Brimonidine Tartrate for the Treatment of Injection Related Erythema | Relapsing-Remitting Multiple Sclerosis (RRMS) | P4 | Withdrawn | — | RCT, Double-blind | peginterferon beta-1a, brimonidine tartrate, Vehicle Gel |
| NCT00246324 Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis | Multiple Sclerosis | P4 | Completed | 16 | Open-label | Interferon beta 1a, oral doxycycline |
| NCT01656148 FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra | Multiple Sclerosis | P4 | Completed | 108 | RCT, Double-blind | Fampridine-SR |
| NCT02683863 Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers | Multiple Sclerosis | P4 | Completed | 20 | Open-label | BG00012 (DMF) (Tecfidera®.) |
| NCT02234869 Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy | Relapsing Multiple Sclerosis | P4 | Withdrawn | — | RCT, Open-label | Interferon Beta, BIIB017 (Peginterferon beta-1a) |
| NCT00492765 Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis | P4 | Completed | 380 | RCT, Double-blind | Interferon-beta-1a, Simvastatin, Placebo |
| NCT02241785 Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies | Relapsing Multiple Sclerosis | P4 | Terminated | 47 | Open-label | natalizumab |
| NCT00179478 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis | Multiple Sclerosis, Optic Neuritis | P4 | Completed | 155 | RCT, Single-blind | interferon beta 1a 30 ug IM once weekly |
| NCT00112034 AVONEX® Combination Trial - "ACT" | Multiple Sclerosis, Relapsing-Remitting | P4 | Completed | 350 | RCT, Double-blind | Methotrexate, IV methylprednisolone |
| NCT02217982 Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation | Relapsing Remitting Multiple Sclerosis | P4 | Terminated | 5 | RCT, Open-label | Simethicone, Loperamide |
| NCT01591551 NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness | Multiple Sclerosis, Relapsing-Remitting | P4 | Completed | 37 | Open-label | Natalizumab (Tysabri) |
| NCT04488133 A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND) | Muscular Atrophy, Spinal | P4 | Completed | 46 | Open-label | Nusinersen |
| NCT01556685 MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia | Multiple Sclerosis | P4 | Completed | 180 | — | — |
| NCT02675413 Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS | Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | P4 | Withdrawn | — | Open-label | Dimethyl Fumarate |
| NCT00871780 A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients | Relapsing Remitting Multiple Sclerosis (RRMS) | P4 | Completed | 224 | Open-label | BG00002 (natalizumab) |
| NCT02342704 Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants | Relapsing-Remitting Multiple Sclerosis | P4 | Terminated | 111 | RCT, Open-label | natalizumab, fingolimod |
| NCT01930708 A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes | Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis | P4 | Completed | 1,114 | Open-label | dimethyl fumarate |
| NCT00915460 Open-Label Safety Extension Study of Avonex | Multiple Sclerosis | P4 | Completed | 408 | Open-label | Interferon beta-1a (Avonex) |
| NCT02090413 Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | P4 | Completed | 241 | RCT, Double-blind | dimethyl fumarate, acetylsalicylic acid, ASA-Placebo |
| NCT00037102 Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis | Multiple Sclerosis | P4 | Completed | 16 | Open-label | interferon beta 1a, methotrexate |
| NCT02125604 Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany | Relapsing-Remitting Multiple Sclerosis | P4 | Completed | 214 | Open-label | dimethyl fumarate |
| NCT02956486 A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease | Alzheimer's Disease | P3 | Terminated | 2,212 | RCT, Double-blind | Elenbecestat, Placebo |
| NCT00660959 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia | Hyponatremia With Normal Extracellular Fluid Volume | P3 | Completed | 106 | RCT, Double-blind | lixivaptan, placebo |
| NCT02623699 An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | P3 | Completed | 176 | RCT, Double-blind | Tofersen, Placebo |
| NCT00876876 International, Multicenter, Open-Label and Randomized Withdrawal Study of Oral Lixivaptan in Heart Failure Patients With Chronic Hyponatremia | Hypervolemic Hyponatremia | P3 | Withdrawn | 300 | RCT, Open-label | Lixivaptan |
| NCT02634307 A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1 | Multiple Sclerosis | P3 | Completed | 1,057 | Open-label | ALKS 8700 |
| NCT00578695 THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation | Hyponatremia | P3 | Completed | 652 | RCT, Double-blind | lixivaptan, Placebo |
| NCT03070119 Long-Term Evaluation of BIIB067 (Tofersen) | ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation | P3 | Completed | 139 | Open-label | Tofersen |
| NCT00090051 FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients | Chronic Lymphocytic Leukemia | P3 | Completed | 552 | RCT, Open-label | Rituximab, Fludarabine Phosphate, Cyclophosphamide |
| NCT00774202 Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP | Immune Thrombocytopenic Purpura | P2P3 | Completed | 17 | RCT, Single-blind | Rituxan, Cyclophosphamide, Vincristine, Prednisone, Higher Dose of Rituximab |
| NCT00673556 A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate | Chronic Plaque Psoriasis | P3 | Completed | 195 | RCT, Double-blind | alefacept, placebo |
| NCT00674063 A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis | P3 | Completed | 78 | RCT, Double-blind | alefacept |
| NCT00443651 A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis | Rheumatoid Arthritis | P3 | Completed | 578 | Open-label | Rituximab, Anti-inflammatory drugs |
| NCT03093324 A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2 | Relapsing Remitting Multiple Sclerosis | P3 | Completed | 506 | RCT, Double-blind | ALKS 8700, Dimethyl Fumarate |
| NCT05418673 A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale | Parkinson Disease | P3 | Terminated | 7 | RCT, Double-blind | BIIB122, BIIB122-Matching Placebo |
| NCT00692172 Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis | Psoriasis | P3 | Completed | 175 | Open-label | Alefacept |
| NCT00876798 A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia | Euvolemic Hyponatremia | P3 | Completed | 206 | RCT, Double-blind | Lixivaptan, Placebo |
| NCT01440101 Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) | Multiple Sclerosis | P2P3 | Completed | 106 | RCT, Double-blind | Natalizumab (BG00002), Placebo |
| NCT04729907 A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD) | Muscular Atrophy, Spinal | P3 | Completed | 115 | Double-blind | Nusinersen |
| NCT01568112 Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate | Healthy | P3 | Completed | 173 | RCT, Double-blind | BG00012 (dimethyl fumarate), BG00012 placebo, ASA, ASA placebo |
| NCT02657356 Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST | Connective Tissue Disease-Associated Pulmonary Arterial Hypertension | P3 | Terminated | 202 | RCT, Double-blind | Placebo capsules, Bardoxolone methyl capsules |
| NCT07483632 A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS) | Relapsing Forms of Multiple Sclerosis | P3 | Not Yet Recruiting | 185 | RCT, Double-blind | Diroximel Fumarate, Dimethyl Fumarate, Fingolimod, Placebo matching DRF, Placebo matching DMF, Placebo matching fingolimod |
| NCT05310071 A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease | Alzheimer's Disease | P3 | Terminated | 1,027 | RCT, Double-blind | Aducanumab, Placebo |
| NCT07444489 A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE) | Antibody-mediated Rejection, Microvascular Inflammation | P3 | By Invite | 201 | Open-label | Felzartamab |
| NCT01351675 Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes | Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2 | P3 | Terminated | 2,185 | RCT, Double-blind | Placebo, Bardoxolone Methyl: 20 mg |
| NCT00168740 Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102) | Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma | P3 | Completed | 150 | Open-label | rituximab |
| NCT05083923 A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS) | Relapsing Forms of Multiple Sclerosis | P3 | Completed | 136 | Open-label | Diroximel fumarate |
| NCT00384150 Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL) | Lymphoma, Non-Hodgkin's | P3 | Terminated | 16 | Open-label | galiximab in combination with rituximab |
| NCT01337427 Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | P3 | Withdrawn | — | RCT, Double-blind | BIIB017 |
| NCT03672175 A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder | Major Depressive Disorder | P3 | Completed | 581 | RCT, Double-blind | SAGE-217, Placebo |
| NCT01622088 Phase 3 Extension Study of Dexpramipexole in ALS | Amyotrophic Lateral Sclerosis | P3 | Terminated | 616 | Open-label | Dexpramipexole |
| NCT01917019 A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis | Multiple Sclerosis, Remittent Progressive, Multiple Sclerosis, Primary Progressive | P3 | Completed | 101 | RCT, Double-blind | Placebo, BIIB041 (fampridine) |
| NCT00835770 BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) | Relapsing-Remitting Multiple Sclerosis | P3 | Completed | 1,736 | RCT, Double-blind | dimethyl fumarate, Placebo |
| NCT00828204 Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects | Multiple Sclerosis | P3 | Completed | 95 | Open-label | BG9418 (interferon beta-1a) |
| NCT01332019 Long-Term Safety and Efficacy Study of Peginterferon Beta-1a | Relapsing Multiple Sclerosis | P3 | Completed | 1,077 | Open-label | peginterferon beta-1a |
| NCT00276172 Open-Label Natalizumab Safety Extension Study | Multiple Sclerosis | P3 | Completed | 1,615 | Open-label | Natalizumab |
| NCT04442503 A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD) | Depression, Postpartum | P3 | Completed | 200 | RCT, Double-blind | SAGE-217, Placebo |
| NCT00297232 Natalizumab (Tysabri) Re-Initiation of Dosing | Relapsing-Remitting Multiple Sclerosis | P3 | Terminated | 1,094 | Open-label | Natalizumab |
| NCT05352919 A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus (SLE) | P3 | By Invite | 864 | RCT, Double-blind | Litifilimab, Litifilimab-matching placebo |
| NCT01235221 Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials. | Multiple Sclerosis | P3 | Completed | 38 | Open-label | BIIB041 (Fampridine-SR) |
| NCT04007367 A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder | Major Depressive Disorder | P3 | Terminated | 53 | RCT, Double-blind | SAGE-217, Placebo |
| NCT00233662 Safety and Tolerability of Repeat Courses of IM Alefacept | Chronic Plaque Psoriasis | P3 | Completed | 400 | Open-label | Alefacept |
| NCT02428218 Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) | Relapsing-Remitting Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis | P3 | Withdrawn | — | RCT, Double-blind | dimethyl fumarate, Placebo |
| NCT02881567 Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab | Relapsing-Remitting Multiple Sclerosis (RRMS) | P3 | Terminated | 41 | Open-label | Daclizumab |
| NCT00223301 Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis | Multiple Sclerosis | P2P3 | Completed | 24 | RCT, Double-blind | Mycophenolate Mofetil (cellcept) |
| NCT02428231 Tecfidera Slow-Titration Study | Multiple Sclerosis | P3 | Terminated | 62 | RCT, Double-blind | dimethyl fumarate |
| NCT00906399 Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis | Relapsing Multiple Sclerosis | P3 | Completed | 1,516 | RCT, Double-blind | BIIB017 (peginterferon beta-1a), Placebo |
| NCT01939002 Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017) | Relapsing Multiple Sclerosis | P3 | Completed | 251 | RCT, Open-label | BIIB017, naproxen |
| NCT00420212 Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | P3 | Completed | 1,234 | RCT, Double-blind | BG00012, Placebo |
| NCT02555215 Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) | Multiple Sclerosis, Relapsing-Remitting | P3 | Completed | 20 | Open-label | dimethyl fumarate |
| NCT02430532 BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Secondary Progressive | P3 | Terminated | 58 | RCT, Double-blind | dimethyl fumarate |
| NCT03068130 Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER | Pulmonary Hypertension | P3 | Terminated | 261 | Open-label | Bardoxolone methyl |
| NCT01416181 A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | P3 | Terminated | 889 | RCT, Double-blind | natalizumab, Placebo |
| NCT00306592 Natalizumab Re-Initiation of Dosing | Multiple Sclerosis, Relapsing-Remitting | P3 | Completed | 404 | Open-label | BG00002 (natalizumab) |
| NCT00027300 Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | P3 | Completed | 900 | RCT, Double-blind | Natalizumab, Placebo |
| NCT02292537 A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA) | Spinal Muscular Atrophy | P3 | Completed | 126 | RCT, Double-blind | Nusinersen |
| NCT00784836 Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients | Multiple Sclerosis | P3 | Terminated | 3 | Open-label | BG9418 (interferon beta 1-a) |
| NCT04476030 A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder | Depressive Disorder, Major | P3 | Completed | 440 | RCT, Double-blind | SAGE-217, Matching Placebo, Sertraline, Escitalopram, Citalopram, Duloxetine, Desvenlafaxine |
| NCT04241068 A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 | Alzheimer's Disease | P3 | Terminated | 1,696 | Open-label | Aducanumab |
| NCT00078611 A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease | Crohn's Disease | P3 | Completed | 462 | RCT, Double-blind | natalizumab |
| NCT00697996 Rituximab for Pediatric Renal Transplant Rejection | Kidney Transplantation | P2P3 | Completed | 20 | RCT, Open-label | Rituximab for transplant rejection |
| NCT04442490 A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD) | Depressive Disorder, Major | P3 | Completed | 543 | RCT, Double-blind | SAGE-217, Placebo |
| NCT00057343 Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | P3 | Terminated | 400 | RCT, Open-label | Zevalin (ibritumomab tiuxetan), Rituxan (rituximab) |
| NCT02477800 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease | Alzheimer's Disease | P3 | Terminated | 1,653 | RCT, Double-blind | Aducanumab (BIIB037), Aducanumab (BIIB037), Placebo |
| NCT05265728 A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | P3 | Terminated | 21 | Open-label | Natalizumab |
| NCT00030966 Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | P3 | Completed | 1,200 | RCT, Double-blind | Natalizumab, Placebo |
| NCT03771664 A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia | Major Depressive Disorder, Insomnia | P3 | Terminated | 87 | RCT, Double-blind | SAGE-217, Placebo |
| NCT03070132 802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia | Trigeminal Neuralgia | P3 | Withdrawn | — | RCT, Double-blind | BIIB074, Placebo |
| NCT01797965 Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 | Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis | P3 | Terminated | 1,501 | Open-label | BIIB019 (Daclizumab) |
| NCT03870763 Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants | Multiple Sclerosis, Relapsing-Remitting | P3 | Terminated | 11 | RCT, Double-blind | Dimethyl Fumarate, Peginterferon Beta-1a, Placebo |
| NCT02978326 A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression | Postpartum Depression | P3 | Completed | 276 | RCT, Double-blind | SAGE-217 15/20 mg Oral Solution, Placebo, SAGE 217 30 mg Capsules |
| NCT00032786 Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease | Crohn's Disease | P3 | Completed | — | RCT, Double-blind | natalizumab |
| NCT03584165 Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa | Choroideremia, X-Linked Retinitis Pigmentosa | P3 | Completed | 277 | Single-blind | — |
| NCT00032799 Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease | Crohn's Disease | P3 | Completed | 905 | RCT, Double-blind | natalizumab |
| NCT02283853 Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) | Relapsing-Remitting Multiple Sclerosis | P3 | Completed | 156 | RCT, Open-label | dimethyl fumarate, Interferon β-1a |
| NCT00915577 Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe | Multiple Sclerosis | P3 | Completed | 74 | Open-label | Interferon beta-1a |
| NCT03496012 Efficacy and Safety of BIIB111 for the Treatment of Choroideremia | Choroideremia | P3 | Completed | 169 | RCT, Single-blind | — |
| NCT01838668 An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) | Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis | P3 | Completed | 225 | RCT, Double-blind | Placebo, dimethyl fumarate |
| NCT02594124 A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies | Spinal Muscular Atrophy | P3 | Completed | 292 | Open-label | nusinersen |
| NCT00451451 Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | P3 | Completed | 1,417 | RCT, Double-blind | BG00012, Placebo, Glatiramer Acetate |
| NCT06044337 A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus | P3 | By Invite | 306 | Open-label | BIIB059 (litifilimab) |
| NCT02097745 A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies | Rheumatoid Arthritis | P3 | Completed | 341 | Open-label | methotrexate, rituximab [MabThera/Rituxan] |
| NCT03918447 A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON | Autosomal Dominant Polycystic Kidney, ADPKD | P3 | Terminated | 667 | RCT, Double-blind | Bardoxolone methyl oral capsule, Placebo oral capsule |
| NCT00106184 Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) | Myositis, Dermatomyositis | P2 | Completed | 200 | RCT, Double-blind | Rituximab, Placebo |
| NCT00290511 Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma | Lymphoma | P2 | Completed | 49 | Open-label | Fludarabine, Mitoxantrone, Rituximab, Zevalin, Dexamethasone |
| NCT02322021 Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease | Alzheimer Disease, Dementia, Alzheimer Type | P2 | Terminated | 70 | RCT, Double-blind | E2609, Placebo |
| NCT00584935 Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid | Ocular Cicatricial Pemphigoid | P1P2 | Completed | 3 | Open-label | Rituximab |
| NCT00588822 Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance | Precancerous Condition | P2 | Terminated | 21 | Open-label | Rituximab |
| NCT00642655 Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation | Kidney Transplant | P1P2 | Completed | 20 | Open-label | IVIG and Rituximab |
| NCT00379587 Rituximab for Prevention of Chronic GVHD | Hematological Malignancies | P1P2 | Completed | 65 | Open-label | Rituximab, 375 mg/m2 RRituximab |
| NCT05348785 A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80 | Parkinson Disease | P2 | Completed | 650 | RCT, Double-blind | BIIB122, BIIB122-Matching Placebo |
| NCT00424749 Rituxan in Churg Strauss Syndrome With Renal Involvement | Churg-Strauss Syndrome | P2 | Terminated | 4 | Open-label | Rituximab, Prednisone |
| NCT01767311 A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease | Alzheimer's Disease | P2 | Completed | 856 | RCT, Double-blind | Lecanemab 2.5 mg/kg, Lecanemab 5.0 mg/kg, Lecanemab 10 mg/kg, Lecanemab 5.0 mg/kg, Lecanemab 10 mg/kg, Placebo, Lecanemab 10 mg/kg |
| NCT00659412 A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis | Psoriatic Arthritis | P2 | Completed | 185 | RCT, Double-blind | Alefacept, Methotrexate, Placebo |
| NCT01713738 Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP) | Idiopathic Thrombocytopenic Purpura (ITP), Immune Thrombocytopenic Purpura (ITP) | P1P2 | Completed | 36 | Open-label | rituximab |
| NCT00298272 Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis | Rheumatoid Arthritis | P2 | Terminated | 54 | RCT, Double-blind | IDEC-C2B8 (rituximab), Placebo, Methotrexate, Etanercept, Adalimumab, Methylprednisolone |
| NCT00280241 Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | P2 | Completed | 65 | Open-label | Fludarabine, Cyclophosphamide, Rituximab |
| NCT00117156 Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma | Lymphoma, Non-Hodgkin, MALT Lymphoma | P2 | Completed | 26 | Open-label | Fludarabine, Rituximab |
| NCT01004081 Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding | Breast Cancer | P2 | Completed | 54 | RCT, Open-label | BIIB021, BIIB021, exemestane (Aromasin) |
| NCT00301002 Study to Evaluate the Efficacy of Alefacept to Treat Palmar Plantar Pustulosis | Psoriasis, Palmoplantaris Pustulosis | P2 | Completed | 15 | Open-label | Alefacept |
| NCT00048737 Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies | Lymphoma, Leukemia | P1P2 | Completed | 70 | Open-label | Zevalin Radioimmunotherapy, Rituximab, Fludarabine, Cyclophosphamide |
| NCT01077466 Natalizumab Treatment of Progressive Multiple Sclerosis | Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | P2 | Completed | 24 | Open-label | Natalizumab |
| NCT03507686 A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111 | Choroideremia | P2 | Completed | 66 | Open-label | BIIB111 |
| NCT00369395 A Study of Volociximab in Metastatic Melanoma | Stage IV Melanoma | P2 | Terminated | 19 | Open-label | volociximab |
| NCT05065970 Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy | Immunoglobulin A (IgA) Nephropathy | P2 | Completed | 54 | RCT, Double-blind | Felzartamab |
| NCT02255435 A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia | Friedreich Ataxia | P2 | Completed | 172 | RCT, Double-blind | Omaveloxolone Capsules, 2.5 mg, Omaveloxolone Capsules, 5 mg, Omaveloxolone Capsules, 10 mg, Placebo, Omaveloxolone Capsules, 20 mg, Omaveloxolone Capsules, 40 mg, Omaveloxolone Capsules, 80 mg, Omaveloxolone Capsules, 160 mg, Omaveloxolone Capsules, 300 mg, Omaveloxolone Capsules, 150 mg |
| NCT04145440 Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) | Glomerulonephritis, Membranous, antiPLA2R Positive | P1P2 | Completed | 31 | Open-label | MOR202 |
| NCT02730455 Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke | Acute Ischemic Stroke | P2 | Completed | 277 | RCT, Double-blind | natalizumab, Placebo |
| NCT04702997 A Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression (MERLIN) | Chronic Kidney Diseases | P2 | Completed | 81 | RCT, Double-blind | Bardoxolone methyl oral capsule, Placebo oral capsule |
| NCT03000569 A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease | Parkinson Disease | P2 | Completed | 29 | Open-label | SAGE-217, Levodopa, Antiparkinsonian Agent(s) |
| NCT03692910 A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode | Bipolar Disorder I, Bipolar Disorder II | P2 | Completed | 35 | Open-label | SAGE-217, Placebo |
| NCT00635193 Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin) | Ovarian Cancer, Primary Peritoneal Cancer | P1P2 | Completed | 138 | RCT, Open-label | M200 (Volociximab), Liposomal Doxorubicin, M200 (Volociximab), M200 (Volociximab) |
| NCT02065375 RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery | Inflammation and Pain Following Ocular Surgery | P2 | Completed | 109 | RCT, Double-blind | Omaveloxolone Ophthalmic Suspension 1.0%, Omaveloxolone Opthalmic Suspension 0.5%, Placebo |
| NCT03318523 Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease | Parkinson's Disease | P2 | Terminated | 357 | RCT, Double-blind | Placebo, BIIB054 |
| NCT00000659 A Phase II Trial of rsCD4 and AZT in Patients With AIDS or Advanced AIDS Related Complex (ARC) | HIV Infections | P2 | Terminated | 80 | Open-label | CD4 Antigens, Zidovudine |
| NCT00493467 Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas | Lymphoma | P2 | Completed | 31 | Open-label | Ibritumomab Tiuxetan (Zevalin), Rituximab |
| NCT03366337 A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX | IgA Nephropathy, CKD Associated With Type 1 Diabetes | P2 | Completed | 103 | Open-label | Bardoxolone methyl capsules |
| NCT00516841 A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer | Ovarian Cancer, Peritoneal Neoplasms | P2 | Terminated | 16 | Open-label | Volociximab |
| NCT00912860 Immunogenicity and Safety Study of Serum-Free Avonex | Multiple Sclerosis | P2 | Completed | 155 | Open-label | Interferon beta-1a |
| NCT00493454 Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas | Lymphoma | P2 | Terminated | 6 | Open-label | Zevalin, Rituximab, ^111 In Ibritumomab Tiuxetan |
| NCT00442780 Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease | Parkinson's Disease | P2 | Completed | 36 | RCT, Double-blind | BIIB014, Placebo |
| NCT05798520 A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) | Relapsing Forms of Multiple Sclerosis | P2 | Completed | 127 | RCT, Double-blind | BIIB091, DRF, Placebo |
| NCT00831649 A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201 | Rheumatoid Arthritis | P2 | Terminated | — | Open-label | natalizumab |
| NCT02959658 Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis | Primary Progressive Multiple Sclerosis | P2 | Completed | 54 | RCT, Double-blind | Dimethyl fumarate, Placebo |
| NCT01864148 Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex | Multiple Sclerosis | P2 | Completed | 419 | RCT, Double-blind | BIIB033, Avonex |
| NCT04733040 Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE) | Glomerulonephritis, Membranous Nephropathy | P2 | Completed | 24 | RCT, Open-label | MOR202 |
| NCT00390221 Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | P2 | Completed | 621 | RCT, Double-blind | BIIB019 (Daclizumab High Yield Process), Placebo |
| NCT00811889 Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease | Chronic Kidney Disease, Type 2 Diabetes | P2 | Completed | 227 | RCT, Double-blind | Bardoxolone Methyl (RTA 402) |
| NCT00664573 104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants | Rheumatoid Arthritis | P2 | Terminated | 339 | RCT, Double-blind | Baminercept alfa (BG9924) |
| NCT01721161 BIIB033 In Acute Optic Neuritis (AON) | Acute Optic Neuritis | P2 | Completed | 82 | RCT, Double-blind | BIIB033 (anti-LINGO-1 mAb), Placebo |
| NCT00438607 Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease | Parkinson's Disease | P2 | Completed | 83 | RCT, Double-blind | BIIB014, Placebo |
| NCT02386553 A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy | Spinal Muscular Atrophy | P2 | Completed | 25 | Open-label | Nusinersen |
| NCT02410200 Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS | Multiple Sclerosis, Relapsing-Remitting | P2 | Completed | 22 | Open-label | dimethyl fumarate |
| NCT01597297 Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis. | Multiple Sclerosis | P2 | Completed | 132 | RCT, Double-blind | BIIB041 (PR Fampridine) |
| NCT00083759 Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate | Rheumatoid Arthritis | P2 | Terminated | 299 | RCT, Double-blind | natalizumab, placebo |
| NCT03339336 Efficacy and Safety Study of BIIB074 in Participants With Small Fiber Neuropathy | Small Fiber Neuropathy, Diabetes Mellitus | P2 | Terminated | 265 | RCT, Double-blind | BIIB074, Placebo |
| NCT02128113 RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD | Corneal Endothelial Cell Loss, Ocular Pain | P2 | Completed | 307 | RCT, Double-blind | Vehicle Ophthalmic Solution, Omaveloxolone Ophthalmic Suspension 0.5%, Omaveloxolone Ophthalmic Suspension 1% |
| NCT00516893 Natalizumab High Titer Immunogenicity and Safety | Multiple Sclerosis | P2 | Completed | 113 | Open-label | BG00002-E (natalizumab high titer) |
| NCT03068468 Study of BIIB092 in Participants With Progressive Supranuclear Palsy | Supranuclear Palsy, Progressive | P2 | Terminated | 490 | RCT, Double-blind | BIIB092, Placebo |
| NCT01703988 An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy | Spinal Muscular Atrophy | P1P2 | Completed | 34 | Open-label | Nusinersen |
| NCT02255422 RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR | MItochondrial Myopathies | P2 | Completed | 53 | RCT, Double-blind | Omaveloxolone capsules, 2.5 mg, omaveloxolone capsules, 5 mg, omaveloxolone capsules, 10 mg, Placebo capsules, omaveloxolone capsules, 20 mg, omaveloxolone capsules, 40 mg, omaveloxolone capsules, 80 mg, omaveloxolone capsules, 160 mg |
| NCT00055367 Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease | Crohn's Disease | P2 | Completed | 30 | Open-label | natalizumab |
| NCT02847598 Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus, Active Cutaneous Lupus Erythematosus | P2 | Completed | 264 | RCT, Double-blind | BIIB059 (litifilimab), Placebo |
| NCT02462759 A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA). | Spinal Muscular Atrophy | P2 | Terminated | 21 | RCT, Double-blind | Nusinersen |
| NCT00031642 Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation | Lymphoma | P1P2 | Completed | 26 | Open-label | rituximab |
| NCT00458861 BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis | Rheumatoid Arthritis | P2 | Terminated | 115 | RCT, Double-blind | BG9924 |
| NCT03745820 A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) | Cognitive Impairment Associated With Schizophrenia | P2 | Completed | 195 | RCT, Double-blind | BIIB104 |
| NCT00135733 A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus | Lichen Planus | P2 | Terminated | 13 | RCT, Double-blind | Amevive (Alefacept), Placebo |
| NCT00292422 Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis | Rheumatoid Arthritis | P2 | Completed | 50 | RCT, Double-blind | BG9924 |
| NCT00664716 Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants | Rheumatoid Arthritis | P2 | Completed | 391 | RCT, Double-blind | Baminercept alfa 1, Placebo, Baminercept alfa 2, Baminercept alfa 3, Baminercept alfa 4, Baminercept alfa 5 |
| NCT00523328 BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861) | Rheumatoid Arthritis | P2 | Terminated | 72 | Open-label | BG9924 |
| NCT05173012 Study to Evaluate SAGE-324 in Participants With Essential Tremor | Essential Tremor | P2 | Completed | 146 | RCT, Double-blind | SAGE-324, SAGE-324 Matched Placebo |
| NCT02036970 Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT | Pulmonary Arterial Hypertension, Pulmonary Hypertension | P2 | Completed | 166 | RCT, Double-blind | Bardoxolone methyl, Placebo |
| NCT01181089 Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS) | Secondary Progressive Multiple Sclerosis | P1P2 | Withdrawn | — | RCT, Double-blind | Placebo, Baminercept |
| NCT00801060 Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL) | Chronic Lymphocytic Leukemia | P2 | Terminated | 40 | RCT, Open-label | Lumiliximab + FCR, FCR |
| NCT00726648 CDP323 Biomarker Study | Relapsing Multiple Sclerosis | P1P2 | Completed | 71 | RCT, Double-blind | CDP323, CDP323, CDP323, CDP323, Placebo |
| NCT01499355 BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis | Lupus Nephritis | P2 | Terminated | 276 | RCT, Double-blind | BIIB023, Placebo, mycophenolate mofetil, oral corticosteroids |
| NCT00119730 Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma | Mantle Cell Lymphoma | P2 | Completed | 30 | Open-label | Fludarabine, Mitoxantrone, Rituximab, Zevalin |
| NCT00005592 Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | Lymphoma | P2 | Completed | 23 | Open-label | 90-Y-ibritumomab tiuxetan, rituximab |
| NCT00055536 Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease | Crohn's Disease | P2 | Completed | 60 | RCT, Double-blind | natalizumab |
| NCT00391066 Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) | Chronic Lymphocytic Leukemia | P2 | Terminated | 627 | RCT, Open-label | FCR + Lumiliximab, FCR |
| NCT02657915 Long-Term Assessment of Remyelinating Therapy | Acute Optic Neuritis | P2 | Completed | 52 | RCT, Double-blind | Placebo, BIIB033 100mg/Kg |
| NCT00193440 Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma | Non-Hodgkins Lymphoma | P2 | Completed | 40 | Open-label | Rituximab, CHOP, CVP, Ibritumomab Tiuxetan |
| NCT02259231 RTA 408 Capsules in Patients With Melanoma - REVEAL | Melanoma, Unresectable (Stage III) Melanoma | P1P2 | Completed | 41 | Open-label | Omaveloxolone Capsules (2.5 mg/capsule), Ipilimumab (3 mg/kg), Nivolumab (240 mg), Omaveloxolone Capsules (10 mg/capsule), Omaveloxolone Capsules (50 mg/capsule) |
| NCT01652937 BIIB057 in Subjects With Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs | Rheumatoid Arthritis | P2 | Withdrawn | — | RCT, Double-blind | BIIB057, Placebo |
| NCT01576887 A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal Dialysis | End-Stage Renal Disease, Type 2 Diabetes Mellitus | P2 | Withdrawn | — | RCT, Double-blind | Bardoxolone Methyl 20 mg, Placebo |
| NCT01051349 Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | P2 | Completed | 410 | Open-label | BIIB019 (Daclizumab), trivalent seasonal influenza vaccine |
| NCT00097760 Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | P2 | Completed | 110 | RCT, Double-blind | Natalizumab, Natalizumab, Placebo |
| NCT01873404 BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy | Painful Lumbar Radiculopathy, Sciatica | P2 | Completed | 183 | RCT, Double-blind | BG00010, Placebo |
| NCT01416155 Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis | P2 | Completed | 97 | Open-label | natalizumab |
| NCT00810836 Efficacy and Safety Study of BG00012 With Methotrexate in Patients With Active Rheumatoid Arthritis | Rheumatoid Arthritis | P2 | Completed | 153 | RCT, Double-blind | BG00012, BG00012, placebo |
| NCT00177554 Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma | Non-Hodgkin Lymphoma | P2 | Completed | 60 | Open-label | Chemotherapy and Radioimmunotherapy |
| NCT03116113 A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112 | X-Linked Retinitis Pigmentosa | P1P2 | Completed | 50 | RCT, Double-blind | BIIB112 |
| NCT07889362 A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN) | Immunoglobulin A Nephropathy | P2 | Not Yet Recruiting | 25 | Open-label | Felzartamab |
| NCT00107861 Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases | Colorectal Carcinoma, Metastases | P1P2 | Completed | 44 | Open-label | Ad.hIFN-β (BG00001, IDEC-201) |
| NCT02133924 Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease | Acute Graft Versus Host Disease | P2 | Completed | 76 | Open-label | natalizumab, steroids |
| NCT01552681 Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome | Primary Sjögren's Syndrome | P2 | Terminated | 52 | RCT, Double-blind | Baminercept |
| NCT00616434 A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis | Active Ulcerative Colitis | P2 | Completed | 123 | RCT, Double-blind | BG9418 (Interferon beta-1a), Placebo |
| NCT03283371 Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy | Epilepsy, Focal Seizures, Partial Seizures | P2 | Completed | 67 | RCT, Double-blind | Natalizumab |
| NCT05021484 Felzartamab in Late Antibody-Mediated Rejection | Antibody-mediated Rejection | P2 | Completed | 22 | RCT, Double-blind | Felzartamab, Placebo |
| NCT00099489 Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | P2 | Completed | 67 | RCT, Double-blind | Interferon Beta-1a |
| NCT01561027 Crossover Study of CNV1014802 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy | Lumbosacral Radiculopathy | P2 | Completed | 82 | RCT, Double-blind | CNV1014802, Placebo |
| NCT00150982 Alefacept Mechanism of Action in Psoriasis | Psoriasis | P2 | Completed | 9 | Open-label | Mechanism of action of alefacept |
| NCT00168701 Efficacy and Safety of BG00012 in MS | Multiple Sclerosis | P2 | Completed | 260 | RCT, Double-blind | BG00012 |
| NCT00870740 Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | P2 | Completed | 517 | RCT, Double-blind | BIIB019 (Daclizumab High Yield Process), Placebo |
| NCT00550849 Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction | Liver Disease | P1P2 | Terminated | 16 | RCT, Double-blind | RTA 402, RTA 402, RTA 402 |
| NCT01930890 BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis | Lupus Nephritis | P2 | Terminated | 87 | RCT, Double-blind | BIIB023, mycophenolate mofetil, oral corticosteroids |
| NCT01538472 Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma | Lymphoma | P1P2 | Completed | 40 | Open-label | Y Zevalin, In Zevalin, Rituxan, BCNU, VP -16, Ara-C, Melphalan, G-CSF |
| NCT01371305 STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis (IPF) | P2 | Completed | 41 | RCT, Double-blind | BG00011, Placebo |
| NCT00048555 Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | P1P2 | Completed | 90 | Open-label | IDEC-114 |
| NCT00535314 Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma | Malignant Melanoma | P2 | Withdrawn | — | RCT, Open-label | RTA 402 Dose1, RTA 402 Dose2 |
| NCT00143806 Transitioning From Cyclosporine to Alefacept in Psoriasis | Psoriasis | P2 | Completed | 13 | Open-label | Transitioning patients from cyclosporine to alefacept |
| NCT00476515 Rituximab Therapy for Patients on Kidney Transplant Waiting List With Positive Donor Specific Crossmatch to Living Donor | Kidney Insufficiency | P1 | Withdrawn | — | Open-label | Rituximab |
| NCT00675701 A Study to Define the ECG Effects of Lixivaptan Compared to Placebo and Moxifloxacin in Healthy Adult Men and Women: A Thorough ECG Study | Healthy | P1 | Completed | 298 | RCT, Double-blind | placebo, lixivaptan, moxifloxacin |
| NCT05005338 A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects | Healthy Volunteers | P1 | Completed | 8 | Open-label | BIIB122 (DNL151), [14C] BIIB122 ([14C] DNL151) |
| NCT05119790 A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male Subjects | Healthy Volunteers | P1 | Completed | 7 | Open-label | [14C] BIIB122 ([14C] DNL151) |
| NCT05909644 An Open-label DDI Study of Omaveloxolone in Healthy Subjects | Healthy Adult Subjects | P1 | Completed | 20 | Open-label | Omaveloxolone, Efavirenz |
| NCT06741657 A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different Ways | Healthy Volunteer | P1 | Completed | 404 | RCT, Open-label | Litifilimab |
| NCT02751905 Absorption, Metabolism, and Excretion Study of BIIB074 | Neuropathic Pain | P1 | Completed | 6 | Open-label | BIIB074 |
| NCT01494701 An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) | Spinal Muscular Atrophy | P1 | Completed | 28 | Open-label | nusinersen |
| NCT02341482 A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects | Healthy | P1 | Completed | 13 | Open-label | PF-04958242, Itraconazole |
| NCT03626012 A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | P1 | Completed | 106 | RCT, Double-blind | BIIB078, Placebo |
| NCT06454721 A Study to Determine the Biodistribution, Safety, and Tolerability of a Microdose of Radiolabeled Diranersen (BIIB080) Co-administered With Diranersen in Healthy Adults | Healthy Volunteer | P1 | Completed | 5 | Open-label | [89Zr]Zr-DFO-Diranersen, Diranersen |
| NCT02459886 Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease | Parkinson's Disease, Healthy | P1 | Completed | 66 | RCT, Double-blind | BIIB054, Placebo |
| NCT02981082 Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension | Systemic Sclerosis, Pulmonary; Hypertension | P1 | Terminated | 6 | RCT, Double-blind | Dimethyl Fumarate (DMF), Placebo Oral Tablet |
| NCT00529438 RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies | Advanced Solid Tumors, Lymphoid Malignancies | P1 | Completed | 47 | Open-label | Bardoxolone methyl |
| NCT00345189 Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors | Tumors, Lymphoma | P1 | Completed | 70 | Open-label | CNF2024 |
| NCT00559702 Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) | Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | P1 | Completed | 76 | RCT, Open-label | natalizumab |
| NCT03324685 A Drug Interaction Study of BIIB074 and an Oral Contraceptive Regimen | Drug Interactions | P1 | Completed | 36 | Open-label | BIIB074, OC (ethinyl estradiol and levonorgestrel) |
| NCT01500798 A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes | Chronic Kidney Disease, Type 2 Diabetes | P1 | Terminated | 18 | RCT, Double-blind | 20 mg bardoxolone methyl, Placebo |
| NCT02551497 Study to Evaluate the Interaction Between a Drug and CNV1014802 in Healthy Subjects | Healthy | P1 | Completed | 36 | RCT, Double-blind | CNV1014802 |
| NCT01052506 BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects | Healthy | P1 | Completed | 72 | RCT, Double-blind | BIIB033, Placebo |
| NCT01238679 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 in Healthy Adult Volunteers | Healthy Volunteers | P1 | Terminated | 20 | RCT, Double-blind | PF-04958242, Placebo |
| NCT01551446 Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes | Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2 | P1 | Withdrawn | — | Open-label | Bardoxolone Methyl |
| NCT03385525 Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmacokinetics of BIIB074 | Drug Interaction | P1 | Completed | 30 | Open-label | BIIB074, Valproic Acid |
| NCT00105170 Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors | Tumors | P1 | Terminated | 13 | Open-label | hCBE-11 |
| NCT00344786 Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL | B-Cell Chronic Lymphocytic Leukemia | P1 | Terminated | 15 | Open-label | CNF2024 (BIIB021) |
| NCT01511510 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers | Schizophrenia | P1 | Completed | 39 | RCT, Double-blind | PF-04958242, PF-04958242, PF-04958242, PF-04958242, Placebo |
| NCT00031083 Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas | Glioblastoma Multiforme, Anaplastic Astrocytoma | P1 | Completed | 12 | Open-label | — |
| NCT02228707 Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers | Healthy | P1 | Completed | 56 | RCT, Double-blind | BIIB061 |
| NCT02269930 Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers | Multiple Sclerosis | P1 | Completed | 30 | Open-label | peginterferon beta-1a, Rebif |
| NCT02951221 New Formulation and Food Effect Study of BIIB074 | Trigeminal Neuralgia (TN), Other Neuropathic Pain | P1 | Completed | 28 | RCT, Open-label | BIIB074 Treatment A, BIIB074 Treatment B, BIIB074 Treatment C, BIIB074 Treatment D |
| NCT01884935 PK and PD Study of Natalizumab in Pediatric Subjects With RRMS | Relapsing-Remitting Multiple Sclerosis | P1 | Completed | 13 | Open-label | Natalizumab |
| NCT02460094 Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | P1 | Completed | 48 | RCT, Double-blind | BIIB092, Placebo |
| NCT04924140 A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 30 | RCT, Open-label | Aducanumab |
| NCT02434718 Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease | Alzheimer's Disease | P1 | Completed | 21 | RCT, Double-blind | Aducanumab, Placebo |
| NCT01518920 A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss | Hearing Loss, Sensorineural | P1 | Completed | 44 | RCT, Double-blind | PF-04958242, PF-04958242, Placebo |
| NCT00956436 Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma | P1 | Completed | 40 | Open-label | BIIB022, Sorafenib |
| NCT01929746 Daclizumab Japanese PK Study | Healthy | P1 | Completed | 56 | RCT, Single-blind | BIIB019 subcutaneous injection |
| NCT03945279 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | P1 | Completed | 49 | RCT, Double-blind | BIIB100, Placebo |
| NCT00674947 A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors | Solid Tumors | P1 | Completed | 55 | Open-label | BIIB015 |
| NCT01244139 Safety Study of BIIB033 in Subjects With Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis | P1 | Completed | 47 | RCT, Double-blind | BIIB033, Placebo |
| NCT01407406 Phase 1 Study to Evaluate the PK, Safety, Tolerability of BIIB023 in Chinese, Japanese, and Caucasian Healthy Volunteers | Healthy Volunteers | P1 | Completed | 48 | RCT, Double-blind | BIIB023 - low dose IV Dose, BIIB023 - high dose IV Dose |
| NCT02201849 A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults | Multiple Sclerosis | P1 | Completed | 104 | RCT, Double-blind | Study Drug, Active Control, Placebo |
| NCT01632449 Study in Healthy Volunteers to Establish the Bioequivalence of Two Different Manufacturers. | Healthy Volunteers | P1 | Completed | 80 | RCT, Single-blind | Test product, Reference product |
| NCT06311786 A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 Moves Through and is Processed by the Body in Healthy Male Participants | Healthy Volunteer | P1 | Completed | 8 | Open-label | [14C]-BIIB091 |
| NCT01281111 Alternate Dosing Regimens of BG00012 in Healthy Volunteers | Healthy | P1 | Completed | 56 | RCT, Double-blind | Dimethyl Fumarate (BG00012), Aspirin, BG00012 matching placebo, ASA matching placebo |
| NCT00526812 A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas | Glioma | P1 | Completed | 54 | Open-label | RTA 744, RTA 744 injection |
| NCT06574828 A Study to Find Out How Multiple Doses of BIIB091 Affect the Electrical Activity of the Heart in Healthy Participants | Healthy Volunteer | P1 | Completed | 69 | RCT, Double-blind | BIIB091, Moxifloxacin, BIIB091-matched Placebo, Moxifloxacin-matched Placebo |
| NCT06612879 A Study to Find Out How BIIB141 (Omaveloxolone) Moves From the Blood Into the Breastmilk of Healthy Women Who Are Breastfeeding or Pumping Milk | Healthy Volunteer | P1 | Completed | 12 | Open-label | Omaveloxolone |
| NCT02833142 Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes | Multiple Sclerosis, Acute Optic Neuritis | P1 | Completed | 28 | RCT, Double-blind | BIIB033 (opicinumab) |
| NCT02294851 A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects | Tauopathies | P1 | Completed | 65 | RCT, Double-blind | BMS-986168, BMS-986168 Placebo |
| NCT01924832 BG00012 Regional Absorption Study | Healthy | P1 | Completed | 32 | Open-label | dimethyl fumarate |
| NCT01749098 A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers | Schizophrenia | P1 | Completed | 29 | RCT, Double-blind | PF-04958242, Ketamine, Placebo, Ketamine |
| NCT01764594 Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus | Immune System Diseases, Autoimmune Diseases | P1 | Completed | 24 | RCT, Single-blind | CDP7657 |
| NCT07149415 A Study to Learn if Taking BIIB141 (Omaveloxolone) Affects How Omeprazole is Processed in the Body and About BIIB141's Safety in Healthy Adults Aged 18 to 55 | Healthy Volunteer | P1 | Completed | 22 | Open-label | Omaveloxolone, Omeprazole |
| NCT01461161 A Single-Dose, Open-Label, Randomized, Food Effect and Blinded, Randomized, Dose Proportionality Study in Healthy Volunteers With Bardoxolone Methyl | Healthy Volunteers | P1 | Completed | 32 | RCT, Double-blind | bardoxolone methyl |
| NCT05618301 Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD) | Sickle Cell Disease | P1 | Completed | 10 | Open-label | Motixafortide, Natalizumab |
| NCT04008186 A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone | Healthy Adult Subjects | P1 | Completed | 61 | Open-label | Omaveloxolone, Midazolam oral solution, Repaglinide 1 MG, MetFORMIN 500 Mg Oral Tablet, Rosuvastatin, Digoxin tablet, Gemfibrozil Tablets, Itraconazole capsule, Verapamil Pill |
| NCT00527410 A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis | Leptomeningeal Carcinomatosis | P1 | Terminated | 9 | Open-label | RTA 744 |
| NCT03902002 A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function | Hepatic Impairment | P1 | Completed | 48 | Open-label | Omaveloxolone 50 mg capsules |
| NCT04056689 Study to Evaluate DNL151 in Subjects With Parkinson's Disease | Parkinson's Disease | P1 | Completed | 36 | RCT, Double-blind | DNL151, Placebo |
| NCT00771329 BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis | Rheumatoid Arthritis | P1 | Completed | 53 | RCT, Double-blind | BIIB023 |
| NCT02029716 RTA 408 Lotion in Healthy Volunteers | Healthy | P1 | Completed | 109 | RCT, Double-blind | RTA 408 Lotion 0.5%, 1%, 3%, Lotion vehicle/placebo |
| NCT02443740 Safety, Tolerability and Pharmacokinetics of BIIB118 (PF-05251749) | Healthy | P1 | Completed | 32 | RCT, Double-blind | BIIB118, BIIB118, BIIB118 |
| NCT01863069 Avonex®: Safety, Blood Levels and Effects | Multiple Sclerosis (MS) | P1 | Completed | 77 | RCT, Double-blind | Interferon beta 1a, (IM) AVONEX® |
| NCT01215084 A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers | Healthy | P1 | Completed | 36 | Open-label | BIIB041 (Fampridine-PR) |
| NCT01424163 Dexpramipexole Japanese PK Study | Amyotrophic Lateral Sclerosis | P1 | Completed | 57 | Open-label | Single dose reduced, Single dose standard, Multiple Dose, Multiple Dose |
| NCT01598363 An Open-Label Study of the Effect of Bardoxolone Methyl on the Single Dose Pharmacokinetics of Digoxin and Rosuvastatin in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 32 | RCT, Open-label | Digoxin, Rosuvastatin |
| NCT00651443 Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma | Lymphoma, Non-Hodgkin's | P1 | Terminated | 20 | Open-label | Galiximab |
| NCT06264440 A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants | Healthy Volunteer | P1 | Completed | 18 | Open-label | BIIB122, Rabeprazole |
| NCT01119781 A Single-Dose, Pharmacokinetic/Pharmacodynamic (PK/PD), & Safety Study of BIIB017 in Participants With Renal Impairment & Healthy Volunteers | Healthy, Renal Insufficiency | P1 | Completed | 35 | Open-label | BIIB017(peginterferon beta-1a) |
| NCT00319930 Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL | Chronic Lymphocytic Leukemia | P1 | Terminated | 10 | Open-label | CNF1010 (17-AAG) |
| NCT00555724 Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors | Solid Tumors | P1 | Completed | 40 | Open-label | BIIB022 |
| NCT00970580 A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | P1 | Completed | 18 | Open-label | BIIB022 With Paclitaxel and Carboplatin |
| NCT02555085 Single Ascending Doses of BIIB063 in Healthy Volunteers | Healthy | P1 | Terminated | 29 | RCT, Double-blind | BIIB063 |
| NCT02831517 PK and Safety Study of BIIB074 in Healthy Japanese and Caucasian Participants | Healthy, Trigeminal Neuralgia | P1 | Completed | 64 | RCT, Double-blind | BIIB074, Placebo |
| NCT02071121 Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect | Healthy | P1 | Completed | 39 | RCT, Double-blind | BIIB061, Placebo, 14C-BIIB061 |
| NCT01689116 Multiple-Dose Study of Effect of Bardoxolone Methyl on QT/QTC Interval Volunteers | Healthy Volunteers | P1 | Completed | 179 | RCT, Double-blind | Bardoxolone Methyl 20mg, Bardoxolone Methyl 80mg, Bardoxolone Methyl Placebo, Moxifloxacin 400mg, Moxifloxacin Placebo |
| NCT01069913 Pharmacokinetics Profile Study of BG00012 Standard Formulation and BG00012 Active Pharmaceutical Ingredient | Healthy | P1 | Completed | 14 | RCT, Open-label | BG00012 |
| NCT06640933 A Study to Find Out How Different Forms of BIIB091 is Processed in The Body With and Without Food in Healthy Participants | Healthy Volunteer | P1 | Completed | 25 | RCT, Open-label | BIIB091 |
| NCT00529113 Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer | Pancreatic Neoplasms, Pancreatic Cancer | P1 | Terminated | 33 | RCT, Open-label | Bardoxolone methyl, Bardoxolone methyl, Bardoxolone methyl, Bardoxolone methyl, Bardoxolone methyl, Bardoxolone methyl, Bardoxolone methyl, Gemcitabine, Placebo, Bardoxolone methyl |
| NCT01453426 Phase 1 Study to Evaluate the PK, Safety, and Tolerability of BG00012 in Chinese, Japanese, and Caucasian Healthy Volunteers | Healthy | P1 | Completed | 71 | RCT, Open-label | BG00012 Dose 1, BG00012 Dose 2 |
| NCT04106050 Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy | Healthy Volunteers, Diabetic Neuropathies | P1 | Withdrawn | — | RCT, Double-blind | BIIB095, BIIB074, Placebo, Lidocaine |
| NCT03716570 A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease | Parkinson's Disease | P1 | Terminated | 24 | RCT, Double-blind | BIIB054, Placebo |
| NCT06064929 A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old | Lupus Nephritis | P1 | Completed | 14 | Open-label | Felzartamab |
| NCT01500408 Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers | Multiple Sclerosis | P1 | Completed | 110 | RCT, Single-blind | Interferon beta-1a (current approved manufacturing process invloving FBS), Interferon beta-1a (new process, manufactured without FBS) |
| NCT00964288 Effect of GSK1014802 on Electrical Hyperalgesia and Threshold Tracking in Healthy Subjects | Pain, Neuropathic, Neuropathic Pain | P1 | Terminated | 16 | RCT, Double-blind | GSK1014802 low dose, Lidocaine, GSK1014802 high dose, Placebo |
| NCT01405833 Study of the Safety, Tolerability, Pharmacokinetics and Safety of BG00010 (Neublastin) in Subjects With Sciatica. | Sciatica | P1 | Completed | 56 | RCT, Double-blind | BG00010 (Neublastin), Placebo |
| NCT04571424 A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian Participants | Healthy Volunteers | P1 | Completed | 33 | RCT, Double-blind | BIIB133 (Dapirolizumab pegol), Placebo |
| NCT00837785 A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS | Relapsing Remitting Multiple Sclerosis | P1 | Completed | 48 | RCT, Open-label | BG00012, BG00012 |
| NCT05148481 A Study to Evaluate Safety and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants | Healthy Volunteer | P1 | Completed | 31 | RCT, Double-blind | BIIB104, Placebo |
| NCT01780246 An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1 (NCT01494701) | Spinal Muscular Atrophy | P1 | Completed | 18 | Open-label | nusinersen |
| NCT02052791 An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246) | Spinal Muscular Atrophy | P1 | Completed | 47 | Open-label | nusinersen |
| NCT01518894 A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia | Schizophrenia | P1 | Completed | 30 | RCT, Double-blind | PF-04958242, PF-04958242, PF-04958242, Placebo |
| NCT01420458 Study in Healthy Volunteers to Establish the BioEquivalence of Two Formulations of BG00012 | Healthy Volunteers | P1 | Completed | 80 | RCT, Open-label | Experimental |
| NCT01313364 A Safety Study in Healthy Volunteers of the Single-Use Autoinjector Containing Placebo of BG9418 Interferon Beta-1a With a 25-Gauge × 1-Inch Needle | Healthy | P1 | Terminated | 80 | Open-label | — |
| NCT02106897 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus, Healthy Volunteers | P1 | Completed | 109 | RCT, Double-blind | BIIB059 (litifilimab), Placebo |
| NCT00955396 Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure | Healthy Volunteer | P1 | Completed | 60 | RCT, Double-blind | GSK1014802, Placebo |
| NCT00000721 An Escalating Dose Tolerance Trial of BG8962 (rCD4) in Patients Who Are HIV Antibody Positive | HIV Infections | P1 | Completed | 85 | Open-label | CD4 Antigens |
| NCT05927649 A TQTc Study for Omaveloxolone | Health Adult Subjects | P1 | Completed | 30 | RCT, Double-blind | Omaveloxolone, Moxifloxacin |
| NCT02359344 PK & Tolerability of CNV1014802 in Young and Elderly Healthy Volunteers | Trigeminal Neuralgia | P1 | Completed | 32 | RCT, Double-blind | CNV1014802, Placebo |
| NCT00488566 GSK Drug Single Dose Escalation And Their Effect On Resting Motor Threshold In Healthy Volunteers | Bipolar Disorder | P1 | Completed | 50 | RCT, Double-blind | GSK drug |
| NCT01416207 A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Safety Study of Avonex® in Chinese Healthy Volunteer Subjects | Healthy | P1 | Completed | 24 | Open-label | Avonex |
| NCT02171208 A Healthy Volunteer Study to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial Manufacturers | Healthy | P1 | Completed | 80 | RCT, Double-blind | dimethyl fumarate - Reference form, dimethyl fumarate - Test form |
| NCT01646840 Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04958242 Compared To A Solution Formulation | Healthy | P1 | Completed | 12 | RCT, Open-label | PF-04958242 capsule, PF-04958242 oral solution |
| NCT02641041 Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants | Central Nervous System (CNS) Demyelinating Disease, Multiple Sclerosis | P1 | Completed | 24 | RCT, Double-blind | BIIB033 |
| NCT01132703 Safety Study of RP-1127 (Glyburide for Injection) in Healthy Volunteers | Traumatic Brain Injury, Stroke | P1 | Completed | 34 | RCT, Double-blind | Glyburide for Injection, Placebo |
| NCT00908154 Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802. | Bipolar Depression, Bipolar Disorder | P1 | Completed | 51 | RCT, Double-blind | Placebo, GSK1014802 |
| NCT01503866 A Phase I Study to Investigate the Absorption, Metabolism and Excretion in Healthy Male Subjects | Healthy | P1 | Completed | 6 | Open-label | bardoxolone methyl |
| NCT03454126 Evaluating the Safety, Tolerability, and Pharmacokinetics of BIIB095 in Healthy Participants | Healthy Volunteer | P1 | Completed | 80 | RCT, Double-blind | BIIB095, Placebo |
| NCT02698267 Effect of Itraconazole on the Pharmacokinetics of BIIB074 | Neuropathic Pain | P1 | Completed | 16 | Open-label | BIIB074, Itraconazole |
| NCT01610310 Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers | Healthy, Multiple Sclerosis | P1 | Completed | 55 | RCT, Open-label | — |
| NCT01365338 A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance Imaging During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy Subjects | Healthy Volunteer | P1 | Completed | 112 | RCT, Double-blind | Placebo, PF-04958242 |
| NCT02521545 Single-Dose Study of a New Formulation of BIIB061 | Multiple Sclerosis | P1 | Completed | 8 | Open-label | BIIB061 |
| NCT00299962 Gene Therapy for Pleural Malignancies | Pleural Mesothelioma, Metastatic Pleural Effusions | P1 | Completed | 17 | Open-label | Adenoviral-mediated Interferon-beta, SCH 721015 |
| NCT01119677 A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 120 | RCT, Double-blind | Avonex |
| NCT02029729 RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER | Metastatic or Incurable Non-small Cell Lung Cancer, Relapsed, Refractory Melanoma | P1 | Completed | 11 | Open-label | omaveloxolone |
| NCT05229562 A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants | Healthy Volunteer | P1 | Completed | 84 | Open-label | BIIB122 |
| NCT03284931 A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia Model | Healthy | P1 | Completed | 45 | RCT, Double-blind | SAGE-217 high dose, Placebo, SAGE-217 low dose |
| NCT02228395 Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers | Healthy | P1 | Completed | 12 | RCT, Double-blind | PF-04958242, Placebo |
| NCT02125578 A Multiple Dose Safety Study of PEG-IFN in Healthy Volunteers | Healthy | P1 | Completed | 69 | RCT, Double-blind | BIIB017 (PEGylated Interferon Beta-1a), Placebo |
| NCT05216887 A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers | Healthy Volunteer | P1 | Completed | 123 | RCT, Open-label | Aducanumab |
| NCT01549769 Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes | Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2 | P1 | Terminated | 24 | Open-label | Bardoxolone Methyl |
| NCT01842126 Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010 (Neublastin) | Painful Lumbar Radiculopathy, Healthy | P1 | Completed | 54 | RCT, Double-blind | BG00010 IV, BG00010 SC, Placebo IV, Placebo SC |
| NCT00913250 A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers | Multiple Sclerosis | P1 | Completed | 96 | RCT, Single-blind | Serum containing Avonex, Serum Free Avonex |
| NCT01035515 BIIB014 Cardiovascular Monitoring Study | Healthy | P1 | Completed | 24 | RCT, Double-blind | Placebo, BIIB014 50mg, BIIB014 100mg |
| NCT04002492 Effects of a Weight Based Training Program on MS Patients | Multiple Sclerosis | N/A | Unknown | 25 | Open-label | — |
| NCT03554343 Sun May Arise on SMA : Newborn Screening of Spinal Muscular Atrophy in Belgium | Spinal Muscular Atrophy | Completed | 136,339 | — | — | |
| NCT05260151 Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases | Alzheimer Disease, Progressive Supranuclear Palsy | Unknown | 155 | — | — | |
| NCT01056848 International, Multicenter Study of a Twenty-eight Week, Open-label, Titrated Oral Lixivaptan Administration in Patients With Chronic Hyponatremia: Extension to Studies CK-LX3401, 3405, and 3430 | Hyponatremia With Normal Extracellular Fluid Volume, Hyponatremia With Excess Extracellular Fluid Volume | Completed | 135 | — | — | |
| NCT00443443 A Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE) | Rheumatoid Arthritis | Completed | 1,026 | — | — | |
| NCT02778438 A Validation Study of the Novel Application of Telehealth in Clinical Drug Development in Subjects With Mild Cognitive Deficits | Mild Cognitive Impairment, Alzheimer's Disease | Completed | 30 | — | — | |
| NCT05058950 An Observational Study Using Multimodal Sensors to Measure Cognitive Health in Adults and Distinguish Mild Cognitive Impairment From Normal Aging | Mild Cognitive Impairment, Normal Aging | Terminated | 22,720 | — | — | |
| NCT04288128 Integrated Functional Evaluation of the Cerebellum | Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 7 | Completed | 40 | — | — | |
| NCT03347370 A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Completed | 626 | — | SC Peginterferon beta-1a, SC interferon beta-1a, SC interferon beta-1b | |
| NCT01532154 Fampridine Pregnancy Exposure Registry | Multiple Sclerosis, Pregnancy | Terminated | 1 | — | Fampridine | |
| NCT03498625 Crohn's Disease Endoscopic REmission Definition in an Objective Way | CD | N/A | Completed | 240 | Open-label | — |
| NCT00884481 Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS | Relapsing-Remitting Multiple Sclerosis, Fatigue | Completed | 195 | — | — | |
| NCT02644083 Tecfidera and MRI for Brain Energy in MS | Multiple Sclerosis | Terminated | 4 | — | Dimethyl fumarate | |
| NCT02323269 Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve) | Multiple Sclerosis, Relapsing-Remitting, Relapsing-Remitting Multiple Sclerosis | Terminated | 24 | — | dimethyl fumarate | |
| NCT03300869 Natural History of Types 2 and 3 SMA in Taiwan | Spinal Muscular Atrophy | Unknown | 300 | — | — | |
| NCT00223457 Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sclerosis | Multiple Sclerosis | Completed | 1,040 | — | — | |
| NCT05197699 Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination Study | Multiple Sclerosis (MS) | Terminated | 160 | — | — | |
| NCT02422407 A Longitudinal, Observational Biomarker Study in Participants With Primary Sjogren's Syndrome | Healthy, Sicca Syndrome | Completed | 100 | — | — | |
| NCT06127095 A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments | Multiple Sclerosis, Relapsing-Remitting | Completed | 474 | — | — | |
| NCT00937677 Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study | Multiple Sclerosis | Completed | 85 | — | Tysabri | |
| NCT01706107 Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants | Relapsing-Remitting Multiple Sclerosis | Terminated | 73 | — | — | |
| NCT04795206 Natural Disease Progression in Participants With Choroideremia | Choroideremia | Completed | 1,178 | — | — | |
| NCT01943526 Ireland Natalizumab (TYSABRI) Observational Program | Relapsing-Remitting Multiple Sclerosis | Completed | 191 | — | natalizumab | |
| NCT02137109 Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri | Multiple Sclerosis | Completed | 400 | — | natalizumab | |
| NCT03593499 Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401 | Melanoma | NO_LONGER_AVAILABLE | — | — | omaveloxolone | |
| NCT01405872 Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™. | Multiple Sclerosis | Completed | 270 | — | — | |
| NCT01070836 JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab | Relapsing Multiple Sclerosis | Completed | 35,895 | — | natalizumab | |
| NCT03359551 Natural History of the Progression of Choroideremia Study | Choroideremia | Completed | 319 | — | — | |
| NCT02839460 A Prospective Study Of Biomarkers Of Skeletal Muscle Atrophy | Sarcopenia | Completed | 30 | — | — | |
| NCT04145284 Quantitative Magnetic Resonance Imaging (MRI) Sub-Study of MS PATHS | Multiple Sclerosis | Completed | 6 | — | — | |
| NCT01211678 Biomarkers of Anti-TNF-α Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive Patients | Arthritis, Rheumatoid | Completed | 301 | — | — | |
| NCT01156298 Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance | Multiple Sclerosis | Terminated | 383 | — | — | |
| NCT00493298 Tysabri Observational Program | Relapsing-Remitting Multiple Sclerosis | Completed | 6,620 | — | Tysabri | |
| NCT05354414 Virtual Reality for the Mitigation of Anxiety During Intrathecal Administration in Participants With Spinal Muscular Atrophy | Spinal Muscular Atrophy (SMA) | N/A | Completed | 63 | RCT, Open-label | — |
| NCT03662919 One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study | Arthritis, Rheumatoid, Spondylitis, Ankylosing | Completed | 2,274 | — | Infliximab, Adalimumab | |
| NCT00464074 Evaluation of Natalizumab for thE Relief of MS Associated FatiGue | Multiple Sclerosis | Completed | 89 | — | — | |
| NCT01211639 Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy | Progressive Multifocal Leukoencephalopathy | Terminated | 24 | — | — | |
| NCT00483847 TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of World | Multiple Sclerosis | Completed | 4,296 | — | — | |
| NCT02440126 Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers for PML Risk Host Markers for PML Risk | Multiple Sclerosis | Completed | 196 | — | — | |
| NCT04103333 Angelman Syndrome (AS) Biomarker Study | Angelman Syndrome, Chromosome 15q Duplication (dup15q) Syndrome | Early P1 | Completed | 20 | Open-label | — |
| NCT05561621 Prediction of Non-motor Symptoms in Fully Ambulatory MS Patients Using Vocal Biomarkers | Multiple Sclerosis | Completed | 70 | — | — | |
| NCT00472992 Pregnancy Exposure Registry for Tysabri® | Crohn's Disease, Prenatal Exposure | Completed | 376 | — | — | |
| NCT04089514 A Real-world Study of Imraldi® Use | Arthritis, Rheumatoid (RA), Axial Spondyloarthritis (axSpA) | Completed | 1,000 | — | Adalimumab | |
| NCT02099370 Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients | Multiple Sclerosis | Completed | 34 | — | — | |
| NCT00477113 TYSABRI Global Observational Program in Safety | Multiple Sclerosis | Completed | 2,207 | — | — | |
| NCT00422617 Evaluate the Efficacy and Safety of One Course of Amevive in Taiwan Patients | Chronic Plaque Psoriasis | N/A | Completed | 40 | Open-label | Alefacept (Amevive) |
| NCT00599274 Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis | Multiple Sclerosis | Completed | 136 | — | Interferon beta-1a, Interferon beta-1a | |
| NCT01945359 Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design | Relapsing Remitting Multiple Sclerosis | Completed | 30 | — | — | |
| NCT01816100 The Effect of Exercise on Strength and Mobility and Corresponding CNS Plasticity in Multiple Sclerosis Patients | Multiple Sclerosis | N/A | Completed | 6 | Open-label | — |
| NCT01489748 Canadian Avonex PEN Productivity Study | Multiple Sclerosis | Completed | 111 | — | — | |
| NCT02996084 MS PATHS Normative Sub-Study | Healthy Volunteer | Completed | 246 | — | — | |
| NCT02386566 Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab | Multiple Sclerosis | Completed | 48 | — | natalizumab | |
| NCT04750785 A Study to Assess Choroideremia (CHM) Health Outcomes | Choroideremia | Completed | 46 | — | — | |
| NCT05109637 A Study to Assess the Clinical Validity of Konectom™ in Adults Living With Neuromuscular Disorders | Spinal Muscular Atrophy | N/A | Completed | 93 | Open-label | — |
| NCT02865109 Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA) | Infantile-onset Spinal Muscular Atrophy | NO_LONGER_AVAILABLE | — | — | Nusinersen | |
| NCT06602921 The Effects of Nitrate, Caffeine, and Cold Exposure on Cardiovascular Function. | Nitrate, Caffeine | N/A | Completed | 24 | RCT, Double-blind | — |
| NCT00675883 COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS | Multiple Sclerosis, Relapsing-Remitting | Completed | 1,000 | — | — | |
| NCT01185717 JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS) | Multiple Sclerosis | Completed | 7,726 | — | — | |
| NCT00618267 ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay. | Multiple Sclerosis | Completed | 100 | — | — | |
| NCT02686268 Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS | C9ORF72 Amyotrophic Lateral Sclerosis (ALS) | Completed | 128 | — | — | |
| NCT01626248 Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control | Multiple Sclerosis | Completed | 164 | — | — | |
| NCT04972487 Expanded Access Program for Tofersen in Participants With Superoxide Dismutase 1-Amyotropic Lateral Sclerosis | Superoxide Dismutase 1-Amyotropic Lateral Sclerosis | APPROVED_FOR_MARKETING | — | — | Tofersen | |
| NCT05446285 Multiple Sclerosis Outcome Determination Evaluating Real Differences After TimE | Relapsing Remitting Multiple Sclerosis | Unknown | 245 | — | — | |
| NCT00463710 Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With MS | Multiple Sclerosis | Completed | 150 | — | Avonex® monotherapy (6.0 MIU administered i.m. each week) | |
| NCT00288990 A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis | Multiple Sclerosis | Completed | 300 | — | — | |
| NCT03662750 TSPO PET as a Measure of Post-stroke Brain Inflammation: a Natural History Cohort | Stroke, Ischemic, Inflammatory Response | N/A | Completed | 3 | Open-label | — |
| NCT04221191 Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP | Multiple Sclerosis, Relapsing-Remitting | Completed | 353 | — | Dimethyl Fumarate | |
| NCT02308657 Multicenter Observational Study of Myotonic Dystrophy Type 1 | Myotonic Dystrophy Type 1 | Completed | 120 | — | — | |
| NCT05097131 An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US | Alzheimers Disease | Terminated | 29 | — | — | |
| NCT05058729 MS PATHS COVID-19 Questionnaire Data Linkage Sub-Study | Multiple Sclerosis (MS) | Completed | 1,507 | — | — | |
| NCT02664324 MSPT Device Usability Study | Multiple Sclerosis | Completed | 60 | — | — | |
| NCT04268147 Instrumented Data Exchange for Ataxia Study | Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2 | Completed | 128 | — | — | |
| NCT04419233 Non-Interventional, Postmarketing Surveillance Study of Nusinersen Sodium Injection | Muscular Atrophy, Spinal | Completed | 50 | — | Nusinersen Sodium Injection | |
| NCT07887828 A Study to Learn More About Friedrich's Ataxia in People Living in the Gulf Cooperation Council (GCC) Region of the World | Friedreich's Ataxia | Not Yet Recruiting | 40 | — | — | |
| NCT04832399 Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants | Relapsing Remitting Multiple Sclerosis | Completed | 60 | — | Natalizumab | |
| NCT02125695 Pilot Tape Harvesting Study | Atopic Dermatitis, Healthy | Completed | 37 | — | — | |
| NCT03218111 Glymphatic Kinetics In Healthy Adult Volunteers | Healthy | N/A | Completed | 19 | Open-label | — |
| NCT01071512 Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis | Multiple Sclerosis | N/A | Completed | 20 | Open-label | Tysabri |
| NCT01330498 Longitudinal Pharmacokinetic, Pharmacodynamic, Immunological, and Biochemical | Multiple Sclerosis | Completed | 229 | — | — | |
| NCT05209815 Safety of Exposure to Natalizumab During Pregnancy | Multiple Sclerosis | Completed | 68 | — | — | |
| NCT02531009 Systemic Sclerosis Clinical and Biomarker Study | Healthy, Systemic Sclerosis | Withdrawn | — | — | — | |
| NCT00707512 CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring | Crohn's Disease | Terminated | 87 | — | natalizumab | |
| NCT00424788 A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS) | Relapsing Forms of Multiple Sclerosis | Early P1 | Completed | 12 | Open-label | natalizumab treatment |
| NCT01070719 Pharmacokinetic, Immunological and Biochemical Sample Collection and Analysis of a Tysabri Patient Cohort | Multiple Sclerosis, Relapse | Completed | 270 | — | — | |
| NCT02776072 Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS) | Multiple Sclerosis | Completed | 2,978 | — | — | |
| NCT02519413 Tecfidera Lymphocyte Chart Review | Multiple Sclerosis | Completed | 483 | — | dimethyl fumarate | |
| NCT02749396 EPID Multiple Sclerosis Pregnancy Study | Multiple Sclerosis | Completed | 2,089 | — | Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG, Extavia (interferon beta-1b), Novartis Pharma AG, Rebif (interferon beta-1a), Merck Serono Europe Ltd, Plegridy (peginterferon beta-1a), Biogen Idec Ltd, Avonex (interferon beta-1a), Biogen Idec Ltd, MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046) | |
| NCT04599023 Assessing the Feasibility of the MSPT Device in Routine Clinical Practice in the Swiss Healthcare System | Multiple Sclerosis, Clinically Isolated Syndrome | Terminated | 182 | — | — | |
| NCT04580381 Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort | Multiple Sclerosis, Relapsing-Remitting | Completed | 500 | — | Natalizumab Injection [Tysabri] | |
| NCT03327454 Benepali® PEN Patient Satisfaction Survey | Rheumatoid Arthritis, Spondyloarthropathies | Completed | 500 | — | Benepali | |
| NCT04756687 Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera | Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Completed | 1,507 | — | Dimethyl fumarate | |
| NCT04746976 Study of Diroximel Fumarate in the Real-World Setting | Relapsing Forms of MS | Terminated | 75 | — | Diroximel Fumarate | |
| NCT01366040 Avonex PEN Satisfaction and Patients Experience Clinical Trial | Multiple Sclerosis | Completed | 89 | — | — | |
| NCT04756700 Validation of DigiCog and Konectom Tools to Support Digitalized Clinical Assessment in Multiple Sclerosis | Multiple Sclerosis | N/A | Completed | 158 | RCT, Open-label | — |
| NCT03487900 Is the Endoscopic Remission Evaluation, Using the CREDO 1 Index / Score in CD Patients in Clinical Remission at Baseline, Predictive of Sustained Clinical Remission Using a 2-year Follow up | CD | N/A | Unknown | 320 | Open-label | — |
| NCT02076841 Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen | Relapsing-Remitting Multiple Sclerosis, Clinical Isolated Syndrome (CIS) | Completed | 40 | — | — | |
| NCT05701423 A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants | Multiple Sclerosis | Terminated | 34 | — | Natalizumab | |
| NCT06089018 Observational Study of Digital Biomarkers of Myotonia and Gait in Adults and Children With Myotonic Dystrophy | Myotonic Dystrophy 1 | Unknown | 125 | — | — | |
| NCT01592474 Evaluation of Brain Atrophy in CIS Patients on Avonex | Multiple Sclerosis | Completed | 180 | — | — | |
| NCT01485003 Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants | Relapsing-Remitting Multiple Sclerosis | Completed | 231 | — | natalizumab | |
| NCT03926637 Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis | Multiple Sclerosis | Terminated | 3,073 | — | — | |
| NCT01480063 An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice | Multiple Sclerosis | Completed | 4,734 | — | Fampridine | |
| NCT02969304 Study of Utilization Patterns of Dimethyl Fumarate in Germany | Multiple Sclerosis | Completed | 930 | — | dimethyl fumarate | |
| NCT00525343 Avonex 15 Year Long Term Follow-up Study | Multiple Sclerosis | Completed | 122 | — | — |